This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Plaintiffs say generic drug companies can't dodge US conspiracy claims

( February 6, 2025, 23:31 GMT | Official Statement) -- MLex Summary: Self-funded direct-action plaintiffs opposed a motion to dismiss US conspiracy claims against Teva Pharmaceuticals, Actavis, Heritage Pharmaceuticals, and other generic drug companies. “The amended complaint adequately alleges conspiratorial conduct for each of the drugs put at issue in Defendants’ motion. If defendants believe plaintiffs lack evidence of illegal conduct regarding certain drugs, they have all the normal discovery tools available to them, and they can file motions for summary judgment at the appropriate time,” they said. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections